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Abstract
Background: It has been well established that research is not addressing health needs in a balanced way — much
more research is conducted on diseases with more burden in high-income countries than on those with more
burden in lower-income countries. In this study, we explore whether these imbalances persist and inquire about
the possible influence of three factors, namely geography, industry and publication incentives.
Methods: We use WHO data on the Global Burden of Disease as a proxy measure of health needs and bibliometric
information as a proxy for research efforts. Scientific publications on diseases were collected from MEDLINE using
MeSH terms to identify relevant publications. We used Web of Science to collect author affiliations and citation
data. We developed a correspondence table between WHO ICD-10 and MeSH descriptors to compare global health
needs and research efforts. This correspondence table is available as supplementary material.
Results: Research output is heavily concentrated in high-income countries and is mainly focused on their health
needs, resulting in a relative lack of attention to diseases in lower income countries. A new finding is that diseases with
a similar burden in high- and middle-income countries are also under-researched, both globally and in relation to
disease burden in high- and middle-income countries. Global industrial R&D is found to be very similar to the focus of
public research. Diseases more prevalent in high-income countries generate ten-fold more research attention than
those in low-income countries. We find no discernible preference towards diseases of high-income countries versus
those of low-income countries in the top 25% most prestigious journals. However, in middle-income countries, citation
rates are substantially lower for diseases most prevalent in low- and middle-income countries.
Conclusions: From a global perspective, the imbalance between research needs and research efforts persists as most of
the research effort concentrates on diseases affecting high-income countries. Both pharmaceutical companies and the
public sector also tend to focus on diseases with more burden in high-income countries. Our findings indicate that
researchers in middle-income countries receive more citations when researching diseases more prevalent in high-income
countries, and this may divert the attention of researchers in these countries from diseases more prevalent in their contexts.
Keywords: burden of disease, unmet health needs, pharmaceutical industry, research priorities, research evaluation,
publication incentives
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Background
The discussion of the 10/90 gap of biomedical research,
which highlights that “only about 10 percent of the global
biomedical research budget is allocated to diseases ac-
counting for about 90 percent of the world’s health prob-
lems”, was first introduced in a report 20 years ago [1,
2]. While this estimate may be out of date, and its accur-
acy disputed [3], the general observation is still relevant.
The lack of balance between disease burden and global
health research attention has been well-documented by
different studies using WHO Global Burden of Disease
data, on the one hand, and different estimates of re-
search effort, such as project funding or publication data,
on the other [4–10]. In order to have more robust infor-
mation on research and development (R&D) investment
on neglected and poverty-related diseases, the G-Finder
initiative and WHO Global R&D Observatory were re-
cently set up [9] (https://gfinder.policycuresresearch.org/
and https://www.who.int/research-observatory/en/).
Despite broad recognition of the scale of this misalign-
ment and a variety of funding initiatives, major imbal-
ances in relative research investment persist [11]. A
larger shift in research priorities is required and, to
achieve it, greater understanding of the factors contrib-
uting to this imbalance is necessary. In this paper, we set
out to explore some of the reasons why research fails to
address some global health needs. In order to capture
patterns that facilitate broad public and policy discus-
sion, we carry out an analysis in terms of the four in-
come levels of countries and five disease types [9]. These
coarse classifications are helpful in capturing the main
trends of disease burden and research attention; how-
ever, they should be complemented with more fine-
grained studies, for example, for specific countries [12,
13] and diseases [14].
Although our interest is on research, it is important to
bear in mind that perceptions of health needs and dis-
ease burdens are affected by a variety of local factors
such as healthcare systems, environmental and living
conditions, cultural preferences, social inequality and ac-
cess to education. In some cases, e.g. in maternal com-
plications, there are medical solutions that are not
implemented or not accessible for part of the population
and more biomedical research is not the solution. There-
fore, research should not solely be driven by disease bur-
den, nor should reducing disease burden be thought of
as solely contingent upon the availability of biomedical
research. A one-to-one relation between research efforts
and burden should not be expected.1
Yet, research efforts are important to address disease
burden in two respects. First, to produce new knowledge
that brings about improvements in the prevention, diag-
nosis, treatment or management of diseases, i.e. to gen-
erate new solutions, but also, and possibly more
importantly, to create capabilities in human resources
and infrastructure for innovation to take place, generally
outside of academia, in hospitals, governments or com-
panies. Innovation studies literature has long claimed
that the main contribution of research is to create cap-
abilities rather than off-the-shelf solutions [15, 16].
We investigate these driving factors using WHO data
from Global Health Estimates on Disability-Adjusted Life
Years (DALYs) for disease burden and Web of Science
publication data as a proxy of amount of research efforts.
We view health and R&D indicators such as those pre-
sented here as proxies that can be questioned and con-
tested. Nevertheless, we believe that they provide
information that can be useful for opening public debates
and suggesting avenues for further research [17, 18].
This paper makes three contributions. First, it provides
an updated comparison of publications against disease
burden that results in new findings regarding the relative
lack of investment in diseases with high burden in
middle-income countries. Second, it explores the driving
factors for the imbalance between research efforts and
global disease burden, including new bibliometric data
regarding pharmaceutical research agendas and citation
incentives. Finally, it makes publicly available a corres-
pondence table between the definitions of the WHO
International Classification of Disease (ICD-10) and the
disease descriptor Medical Subject Headings (MeSH) of
the United States National Library of Medicine.
Establishing the factors influencing research agendas is
extremely difficult because they are shaped by many
interacting social, economic and political factors [19–
22]. As Gläser and Laudel highlight, “researchers need to
select problems and approaches that create a sufficient
agreement between their own interests, the [scientific]
community’s expectations concerning relevant and reli-
able contributions, and expectations by external actors”
([21], p. 436). In this study, we limit the exploration to
three potential factors – research prioritisation driven by
national (rather than global) health needs; the influence
of pharmaceutical companies; and incentives to publish
in prestigious journals and on highly cited topics. There
are other factors influencing the choice of disease topic
that we do not explore here; most importantly, the ex-
pectation that progress can be achieved by doing re-
search in a certain field – whether research is needed
and whether the problems are practically ‘doable’ [23].
Given that most public research is funded and gov-
erned at the national level, it should be of no surprise
that research priorities are more balanced in relation to
1Hagenaars et al. [7] propose to compute the disease burden based on
its value in the quartile of countries where it is the lowest, since this
value signals the disease burden according to the best available
knowledge applied.
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national health needs than to global health needs. A
higher correlation between health needs and research at
the national level is indeed observed [5]. However, since
knowledge production is heavily concentrated in high-
income countries (HICs) [24] but overall disease burden
is higher in low- and middle-income countries (LMICs),
one can expect a great lack of balance between global re-
search and global health needs. One can nevertheless
wonder whether priorities in LMICs are driven by their
own needs.
A second prominent factor is market demand. Accord-
ing to Røttingen et al. [9], private companies make up
around 60% of the total health R&D, with pharmaceut-
ical companies leading this investment. For example,
companies such as Roche spend around 9bn Euro per
year in R&D (https://ec.europa.eu/info/news/2018-in-
dustrial-rd-scoreboard-eu-companies-increase-research-
investment-amidst-global-technological-race-2018-dec-1
7_en), which is about seven times the budget of a major
funder of biomedical research such as the Wellcome
Trust. Prior research has indicated that the majority of
market demand for health research is found within
chronic conditions predominantly affecting individuals
in HICs. As a result, research funded by pharmaceutical
companies most often investigates these diseases [25–
27]. This funding from industry is likely to indirectly in-
fluence the topic selection of researchers, even when the
studies are funded with public money. In other words,
pharmaceutical research priorities are likely to ‘spillover’
into public research priorities. Indeed, Evans et al. [5]
found that the global health research efforts were posi-
tively related to market for treatment but negatively re-
lated to global disease burden.
A third factor influencing research agendas is the aca-
demic prestige and evaluation pressure associated with
norms and incentives within scientific institutions. This
influence may be indirect and informal, through the se-
lection of topics that are seen as prestigious within a cer-
tain scientific community, and are thus likely to
contribute positively to researchers’ career develop-
ments. Alternatively, it can also be fully institutionalised
in national evaluation systems that reward scientific visi-
bility, often proxied through either the prestige of the
journals that the authors publish in (generally via the
Journal Impact Factor (JIF)) or the number of citations
their publications receive [28].
These forms of assessment may be harmful when used
without care [29, 30] and, in some cases, may incentivise
researchers in ‘peripheral’ countries (not only in LMICs,
but also in some ‘peripheral’ HICs like Italy or Spain) to
conduct research that is relevant for large HICs rather
than focusing on local or national needs [31–34]. In the
case of health, the hypothesis is that diseases more
prevalent in HICs are more likely to be published in
prestigious journals (e.g. with higher JIF), get more cit-
ation attention, and may thus be more attractive for the




We used the Years of Life Lost and DALYs provided by
WHO in 2017 as a proxy of the burden of disease [35].
Although DALYs are not free of limitations, they are
one of the most established proxies of disease burden
[36–38]. We used the DALY estimates for 2010 in order
to analyse (via publications) whether research responded
to health needs in 2010 in the following years (2010–
2014). Additionally, choosing this time segment allowed
for a detailed analysis of the citation impact of the publi-
cations published between 2010 and 2014. Our analysis
is based on the 134 specific diseases within the groups of
diseases (1) communicable, maternal, perinatal and nu-
tritional conditions and (2) non-communicable diseases
(Additional file 3).
Bibliometric methods for estimating research efforts on
disease
We relied on scientific publications as a proxy of the re-
search effort made on different diseases for the period
2010 to 2014. These publications were collected from
MEDLINE in May 2019 through the MeSH terms that
best describe the 134 diseases considered in the analysis.
We built a concordance table between ICD-10 (classifi-
cation used by WHO) [35] and MeSH terms. Despite
some serious limitations, we expect the data to capture
general trends and dynamics reflecting some aspects of
the research conducted on these diseases. The Centre
for Science and Technology Studies (CWTS) in-house
version of the Web of Science was used to retrieve add-
itional information from publications such as the institu-
tional affiliations of the authors and the number of
citations received by these publications. We limited the
analysis to articles and reviews. Figure 1 provides a sum-
mary of data collection methods.
Classification of countries by income groups
Publications are attributed to countries on the basis of
the authors’ country of affiliation using fractional count-
ing. We grouped countries into four categories, accord-
ing to their income level in the year 2010, following the
World Bank’s historical classification of countries by in-
come (https://datahelpdesk.worldbank.org/knowledge-
base/articles/906519-world-bank-country-and-lending-
groups) as HICs, upper–middle-income countries
(UMICs), lower–middle-income countries (LoMICs) and
low-income countries (LICs). It is important to keep in
mind that certain countries contribute to a large
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proportion of the overall scientific production of their
income level group. For example, the United States rep-
resents 35% of publications of HICs, China produced
half of the publications in the UMICs group and India
produced 60% of all publications in LoMICs.
Classification of diseases by relative burden over HICs or
LMICs
We grouped the 134 diseases considered in the analysis
into five disease types according to their relative burden in
HICs and LICs. This categorisation is based on a modified
version of the WHO framework developed in 2012 [9, 39].
The initial categorisation classifies diseases as type 1, 2
and 3, depending on whether the burden generated by the
diseases is relatively larger in HICs or in LMICs. Given
that type 1 was very large, we further split the group of
diseases into type 1a (more burden per capita in HICs),
type 1b (equal burden in HICs and LMICs) and type 1c
(just a bit more burden in LMICs), inspired by the work
by von Philipsborn et al. [10], as described in Table 1. The
assignment of specific diseases to types can be found in
supplementary Additional file 2.
Journal impact factor analysis
We collected the JIF of the journals where the articles
included in our analysis where published. This informa-
tion was extracted from the Clarivate Analytics’s Journal
Citation Reports. The impact factor (IF) reflects the
average frequency with which articles published in a
given journal are cited in a given period of time. Based
on all IFs, we were able to determine the quartile to
which the journal belongs. We followed the same
procedure as in the Journal Citation Reports (http://
help.incites.clarivate.com/inCites2Live/indicatorsGroup/
aboutHandbook/usingCitationIndicatorsWisely/jifQuar-
tile.html) to obtain these quartiles, so that quartile Q1
groups the 25% of journals with the highest IFs within a
given subject category.
Citation analysis
We have computed two citation-based indicators as
proxies of the scientific impact of publications. The first
indicator is the Mean Normalised Citation Score, which
reflects the average citation impact of a set of publica-
tions. The second measure indicates the proportion of
publications produced by a given aggregate that belong
to the top 10% most frequently cited worldwide. Both
indicators are normalised by scientific field and publica-
tion year. This means that the publications we included
in our analysis are compared to publications published
worldwide the same year and in the same scientific field
[40, 41].
Further details on data and methods can be found in
the supplementary Additional file 1. The data of the fig-
ures, including some complementary information, is
available in Additional file 2. The concordance table is
available in Additional file 3.
Research collaboration
Several studies have systematically found a strong rela-
tionship between research conducted in collaboration,
especially international collaborations, and citations [42,
43]. In order to account for the possible influence of col-
laboration in analyses of citation impact, we have distin-
guished between publications with and without
international collaboration. We considered publications
listing two or more different countries in the affiliations
of the authors to be produced in international
collaboration.
Publications produced and funded by the pharmaceutical
industry
We have considered 23 large pharmaceutical companies
in order to analyse the priorities of big pharma across
disease types. Thus, instead of considering an exhaustive
list of companies active in the pharma sector, we focus
on the largest companies in the sector, which are those
funding more research to academia.
We have identified two groups of publications related
to big pharma – (1) publications (co-)authored by re-
searchers working at these companies and (2) publica-
tions that acknowledge that the research has been
conducted with financial support from these companies.
Further details on the identification and process of this
information is provided in the supplementary materials
(section S1.3) and the website www.cwts.nl/bigpharma.
Fig. 1 Summary of the data collection strategy of disease burden
and publication data
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Results
Comparison of global disease burden versus global
research efforts
Figure 2a shows that HICs produce a disproportionately
large number of publications (close to 80%) compared to
the percentage of the global population living in these
countries (16%) and the disease burden affecting them
(10%). On the contrary, LMICs make up roughly 85% of
the global population and 90% of the global disease bur-
den, while they only produce around 20% of publications.
It is worth highlighting as well that UMICs produce most
of the research outside HICs (17% of total). UMICs in-
clude China, most of Latin America, Russia and South
Africa (Fig. 2b). LoMICs, whose production is dominated
by India, account for 3.4% of publications. LICs only pro-
duce 0.6% of the world’s publications.
Figure 3a shows the relative (%) disease burden
against the relative (%) of publications for various dis-
ease types (listed in Table 1 below). We observe that,
although global disease burden is quite spread across
disease types, the percentage of publications declines
steadily from type 1a (similar prevalence in HICs and
in LMICs) to type 3 (more prevalent in LMICs than
in HICs). Type 1a account for the lowest percentage
of disease burden worldwide (13%) but the largest
share (34%) of scientific publications. In contrast, type
3 diseases make up only 4% of the world’s publica-
tions while contributing to 14% of the global disease
burden.
Figure 3b shows the ratio of the relative research effort
over the relative disease burden. This ratio is an estimate
of investment per unit of disease burden (% of publica-
tions over % of DALYs for a disease type). Type 1a dis-
eases have ten times more publications per DALY than
type 3, five times more than type 2, and two times more
than type 1b. The figure suggests that R&D investments
have a strong systematic imbalance against the diseases
mainly or only affecting LMICs.
The geographic distribution of disease burden and
research efforts
Given that the relative burden of diseases are unequal
across geographical regions and countries of disparate
income level, it is to be expected that research efforts
also follow national patterns [5].
Figure 4a shows the distribution of DALYs across
disease types for different income levels. We observe
that type 1a and 1b make up more than 70% of the
burden in HICs, whereas types 2 and 3 account for
more than 70% of the burden in LICs. MICs show
transition patterns, with their highest burden shifting
from type 1b and type 1c (high in UMICs) to type 2
(high in LoMICs).
Publication distributions show similar patterns
across income country level, as illustrated in Fig. 4b.
In HICs, publication shares by disease type decrease
steadily from type 1a to type 3, whereas in LICs, we
observe that both type 2 and type 3 diseases consti-
tute research priorities, with almost 70% of the publi-
cations. These results are thus in agreement with
Confraria’s [44] findings that African health research
focuses on their pressing health needs and that inter-
national collaboration and funding supports this
focus. Nevertheless, the number of publications by
HICs is so much larger than that of LMICs that the
3% of HIC publications devoted to type 3 diseases
amounts to more than half (58%) of all publications
worldwide devoted to type 3 diseases, while the 36%
of LIC publications on type 3 amounts to only 6% of
the global production (shown in Fig. S3, Additional
file 2).
It should be noted that there are some interesting
departures from ‘alignment’ (better observed in Fig. 4)
that show the ratio of the % of publications over the
% of DALYs. First, we observe that HICs conduct
much more research on types 2 and 3 (six-fold and
two-fold, respectively) than could be expected from
their own disease burden. Such research capacity in
HICs for diseases occurring almost exclusively in LICs
can be explained by HIC’s colonial legacies and pro-
grammes of international cooperation [11]. UMICs
also conduct more research on type 3 diseases than
would be expected (two-fold). This is understandable
since countries like Brazil are potentially vulnerable
to and have a historical expertise in tropical and
neglected infectious diseases.
Table 1 Classification of diseases according to differences of burden per capita in low- and middle-income countries (LMICs)
compared to high-income countries (HICs)
Type Relative disease burden per capitaa Description # Diseases Exemplary cases
1a < 0.75 More burden in HICs 34 Colon cancer, breast cancer, Alzheimer’s disease
1b 0.75≤ x < 1.25 Equal burden 28 Depression, schizophrenia, ischemic heart disease
1c 1.25≤ x < 3.00 A bit more burden in LMICs 26 Cirrhosis, stroke
2 3.00≤ x < 35.0 More burden in LMICs 22 Maternal conditions, HIV
3 ≥ 35.0 Quasi exclusive of LMICs 24 Malaria, diarrhoeal diseases
aRelative disease burden per capita is calculated as the ratio of disease burden per capita in LMICs over disease burden per capita in HICs [10]
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More unexpectedly, though, is the observation that MICs
conduct more research than would be expected from their
observed disease burden on the diseases that are most rele-
vant to HICs. In UMICs (with China as main contributor),
type 1a diseases account for 30% of publications, although
their burden is only 19%. However, types 1b and 1c, which
have the largest burden (more than 60%) in UMICs, make
less than 50% of publications. Similarly, in LoMICs (which
is dominated by India’s production), type 1a diseases get a
three-fold attention above expectation, whereas type 2
(which is by far the largest, with 34% of DALYs) and type 3
are relatively under-researched. These imbalances point to
potential problems in the priorities of UMICs and LoMICs
and deserve further analysis.
The focus of pharmaceutical research efforts
Most details on big pharma’s research priorities are not
public. However, it is possible to estimate their relative re-
search efforts through their own publications, and the
publications that acknowledge their funding, which are
mainly by universities doing contract research for them.
Although the number of these publications is relatively
small (of the order of 12,000 published and 12,000 funded
per year against 600,000 articles and reviews published on
health areas per year), these companies do conduct con-
siderable amounts of R&D. In fact, it is estimated that
business expenditure makes up about 60% of global health
R&D [9]. Companies such as Roche have budgets of the
order of 10bn US$, whereas government R&D
a
b
Fig. 2 a Population, disease burden (DALYs) and publications by country income level. b Geographical distribution of country income levels
(World Bank)
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expenditure in health is of the order of 1–2bn US$ in
countries like the United Kingdom, France or Germany.
Thus, the large scale of pharma R&D expenditure suggests
that it is likely to influence researchers’ priorities, even if
their number of publications are modest.
Here, we provide data on the research focus of
Fig. 5 and show the relative research efforts of big
pharma by disease type that were published (orange)
and funded (brown) by 23 pharmaceutical companies.
A list of publication trends and specialisation patterns
by specific diseases of these 23 companies is available
at http://www.cwts.nl/bigpharma. Since big pharma
companies may be expected to follow market de-
mands rather than health needs, it is not unexpected
that they publish and fund more research in type 1a
diseases than in other types. Rather surprisingly is the
extent to which their publication and funding patterns
reflect those of all publications on diseases, which are
mainly conducted by public research organisations.
One would expect public research to focus on
topics other than those focused on by private re-
search. Indeed, one can make the ‘market failure’ ar-
gument, namely that public research priorities should
be set in a way to fill gaps in knowledge that would
a
b
Fig. 3 a Global percentage of DALYs and publications by disease type. b Relative research effort in relation to disease burden by disease types
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otherwise receive relative under investment if left to
market mechanisms. However, the similarity in prior-
ities observed suggests that public and private bio-
medical research are strongly coupled. It seems
plausible that big pharma shapes research priorities
by funding part of the research in public labs as well
as influencing a variety of decision-making processes




Fig. 4 a Distribution of burden (DALYs) across disease types per income level. b Distribution of publications across disease types per income
level. c Relative research efforts for each disease type per income level
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Journal prestige and citation patterns across disease
types
Academic reputation is another factor that may be influ-
encing research topic selection. It is often argued that
research topics not relevant for HICs are less likely to be
accepted in prestigious journals and attract attention
(and citations!) [31, 34]. We have examined these hy-
potheses in the ensuing analyses.
Figure 6a shows the percentage of publications in the
top quartile of JIF (Q1)2 across disease types. This choice
of Q1 follows a conventional ‘quality’ criterion in formal
evaluation practices [28]. The choice of Q1 is highly
problematic as an indicator of ‘quality’ [30], but it may
represent the pressure experienced by researchers via
both formal and informal evaluation regimes. The pat-
tern observed does not support the hypothesis that dis-
eases with more burden in LMICs are less likely to be
accepted in Q1 journals. In fact, type 2 and 3 diseases
are published in Q1 journals slightly more often than
type 1a and 1b.
Figure 6b shows two indicators of citation impact
across disease types. In this case, we find that type 1a
and 1b diseases receive more citations than type 1c and
2, which are cited more often than type 3. The differ-
ences in citation are substantial – type 1a diseases get an
18% boost while type 3 receive 16% less citations than
expected. Thus, the observations on JIF and citations
offer different insights – diseases relevant for LMICs are
equally accepted in high impact journals, but they re-
ceive less citations.
Next, we examined the distribution of Q1 and cita-
tions by country income level. In doing so, we found dif-
ferent patterns for publications produced with and
without international partners. For LMICs, international
publications have much higher JIF and citation rates
than those without international partners. Since inter-
national collaborations account for about 20% of publi-
cations in HICs and MICs, but 75% of LICs (Fig. S4 in
Additional file 2), this results in the artefact that LICs
show higher citation rates than MICs. Therefore, for the
sake of understanding the local capabilities to publish in
prestigious journals and be cited, it is more informative
to use publications produced by domestic research orga-
nisations only (Fig. 7a,b).
Figure 7a shows the percentage of publications in Q1
produced exclusively by domestic organisations across
income classes. The percentage is rather similar in all
disease types within each of the income levels, except for
type 3, which has a higher proportion of publications in
Q1. In the case of LoMICs and LICs, this proportion of
Q1 is much higher, suggesting that they have a
Fig. 5 Relative research effort by disease type by ‘big pharma’
2In other words, this indicator is the percentage of publications in
journals that belong to the 25% of journals with the highest JIF within
their Web of Science Subject Category, in the year when the article
was published.
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significantly higher expertise in type 3. Therefore, this
observation questions the hypothesis that publishing in
high impact journals is more difficult on diseases of
LMICs.
Yet, when we turn to the citation impact, we see
very different patterns at each income level (Fig. 7b).
HICs achieve a similar citation impact in all disease
types, with the highest for type 3. In LICs, citation
impact increases steadily from type 1a to type 3, in
accordance with its research specialisation. However,
in UMICs and LoMICs, the opposite pattern is ob-
served, i.e. citation rates decrease as one gets closer
to type 3 diseases. This pattern may constitute a
problem since it creates an incentive that does not fit
with the needs suggested by the disease burden pro-
files in Fig. 3a. This possibility is particularly likely
since many UMICs have individual evaluation or in-
centive schemes based on rather mechanistic biblio-
metric criteria, although often based on JIF quartiles
rather than citations [28].
a
b
Fig. 6 a Percentage of papers published in Q1 journals, by disease type. b Citation impact by disease type. Right axis: PPTop10% Percentage of
publications among the top 10% most cited. Left axis: MNCS mean number of citations per Web of Science Subject category
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Discussion
In this article, we have analysed patterns of disease bur-
den in DALYs against research efforts as shown by pub-
lications across four country income levels and five
disease types related to degree of burden by high/low in-
come level. The study updates and corroborates previous
analyses on the gap between global health needs and re-
search efforts [10]. We find that type 1a diseases, with
higher burden in HICs, receive ten-fold more research
attention than diseases (type 3) affecting only LICs
(Fig. 2b). A new finding is that the diseases affecting
HICs and LMICs equally, and UMICs relatively more
(types 1b and 1c), also receive two- to three-fold less
attention.
We explored some of the key potential factors driving
these imbalances of attention. First, we observe that
health research is highly concentrated (80%) in HICs. As
a result, it tends to focus on diseases more prevalent in
these countries [5]. Even if efforts are made by some
HICs to contribute to global health, these are insufficient
to compensate for inequalities in R&D expenditure
across countries. However, in the case of UMICs, we ob-
serve some problematic deviations from the expected
patterns. Although UMICs contribute above expectation
a
b
Fig. 7 a Percentage of papers published in Q1 journals, by disease type and income level (only publications with no international collaboration).
b Citation impact by disease type and income level (only publications with no international collaboration) PPTop10% Percentage of publications
among the top 10% most cited
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to the study of type 3 diseases, they also produce many
more papers (1.5-fold more) than expected according to
their own health needs on type 1a diseases (Fig. 4c) and
less than expected (some 17% and 27% less) on type 1b
and type 1c diseases. This observation suggests that, in
UMICs, there might exist incentives, either in terms of
funding or academic rewards, for researchers to publish
in type 1a diseases.
Second, we observe that research conducted by
pharma is also skewed towards type 1a and 1b diseases.
The patterns of disease focus found for research pub-
lished or funded by 23 big pharmaceutical companies
are surprisingly similar to those found in public re-
search. This suggests a strong coupling between private
and public R&D in biomedical research.
Third, we do not find diseases more prevalent in
LoMICs and LICs (types 2 and 3) to be underrepre-
sented in the most prestigious journals of disciplines (in
the top quartile of journal impact factor) – against the
expectations of the literature studying marginalisation in
mainstream journals of the topics specifically relevant to
developing countries [31, 34, 46]. On the contrary,
UMICs publish a bit more in top journals on types 2
and 3, while LICs publish much more. Given this pat-
tern, LICs are found to have more citations in type 2
and 3 diseases, even when considering only domestic
publications (Fig. 5b). Nevertheless, publications of types
1a and 1b have more citations than those of types 2 and
3 in aggregate (Fig. 4b). Importantly, this is also true in
the domestic publications of MICs. These results are
surprising – on average, in countries like China, India or
Latin America, researchers may gain more citation im-
pact if they publish in diseases with the highest burden
in the global north. Those researchers in MICs receive
more recognition when studying diseases that are not, in
relative terms, in the top health priorities of their own
context. This finding deserves further careful analysis at
more fine-grained levels of aggregation to check its
robustness.
The two main new findings of this paper concern the
publication and citation impact of MICs. While there is
a large volume of literature on poverty-related and
neglected diseases [10], the analysis is generally focused
on diseases affecting LICs. We are not aware of previous
studies showing that diseases type 1b and 1c, which have
a similar or slightly lower burden in HICs and LMICs,
are relatively understudied. UMICs have now become a
sizeable part of global science, accounting for 17% of
disease-related publications worldwide. We have shown,
first, that their research is partly focused (unlike that of
LICs) towards diseases of HICs (type 1a). Second, we
have found that, in UMICs, researchers may gain more
citations by studying type 1a and 1b diseases, which may
partially explain this deviation. This finding, which is still
very speculative, would lend some credibility to the hy-
pothesis that evaluation systems based in MICs divert at-
tention away from their national contexts towards those
of HICs. However, we also report that type 2 and 3 dis-
eases appear as equally likely as type 1 to appear in pres-
tigious journals and, in fact, formal incentive and
evaluation programmes are more based on journal pres-
tige than on citations received.
Limitations and further research
This is an exploratory analysis with a variety of limita-
tions that will benefit from further research. In the first
place, DALYs are only one of the various possible forms
to estimate disease burden – estimates based on other
assumptions or understandings of health needs or well-
being might yield different results [17, 36–38, 47]. Sec-
ond, our bibliometric data is based on a database (Web
of Science), which has been shown to underrepresent re-
search LMICs [48, 49], and our search strategy is based
on MeSH terms, which may overlook some non-
biomedical publications. Third, the simple classifications
of countries and diseases used are helpful in providing
general patterns, but these general patterns should not
be used to infer conclusions for individual countries
given the risk of ecological fallacy. More fine-grained
analyses are necessary, in particular given that large
countries such as the United States (in HICs), China (in
UMICs) and India (in LoMICs), strongly shape the re-
sults of their income level categories. Finally, we should
keep in mind that, in order to improve the impact of re-
search in global health, it is also necessary not only to
address the relevant diseases, but also to improve other
research strategies or approaches [1, 19]. In particular, it
may be important to provide further support studies for
implementation science or health systems research [11].
Conclusions
In this study, we have corroborated that the relative im-
balance of global health research to diseases most preva-
lent in poor countries can be mainly explained by the
concentration of research in rich countries, where fund-
ing and incentives are likely to be driven by national ra-
ther than global needs [5]. We have also shed some light
on two further mechanisms contributing to the lack of
balance across health needs [20]. First, we have shown
pharmaceutical companies focus on diseases with more
burden in HICs (and thus larger market demand), which
is likely to incentivise public researchers funded by in-
dustry to direct their research towards these diseases.
Additionally, we have found that researchers in MICs re-
ceive more citations when conducting research on dis-
eases more prevalent in HICs. This may constitute
another incentive to publish in these areas, at the ex-
pense of other diseases more prevalent in their contexts.
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Given that mainstream institutional structures tend
to steer research on diseases more prevalent in HICs,
policy initiatives will be needed for increasing re-
search on diseases that are relatively unattended.
First, as indicated by many previous studies, policies
should encourage increasing the attention given to
poverty-related and neglected diseases and a “greater
focus on actual knowledge exchange and transfer be-
tween LMICs and HICs ( …), leading to strengthening
of research capacity in the former” [11]. Second, pub-
lic and charity research funders should be aware of
the potential influence of the pharmaceutical industry
on public research system and balance their research
portfolios in accordance to perceived needs and op-
portunities [50]. Third, it provides some (though not
conclusive) evidence that, in MICs, notions of aca-
demic prestige based on citations might be a disin-
centive to work in diseases relevant to their context.
This finding feeds into the discussion on the (per-
verse) effects of scientific reward systems in these
countries, and the debate on introducing assessment
criteria that directly support impact in health out-
comes [31, 51].
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